Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 11Neoplasm Metastasis 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence Free Survival 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Histiocytosis 1Fallopian Tube Neoplasms 1Erythema 1Endometrial Neoplasms 1Edema 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Gemcitabine 57130-nm albumin-bound paclitaxel 35Specimen Handling 26Magnetic Resonance Spectroscopy 21Albumin-Bound Paclitaxel 21Fluorouracil 20Leucovorin 19Irinotecan 19Oxaliplatin 17Biopsy 17Taxes 16pembrolizumab 13Cyclophosphamide 11Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8Nivolumab 7Carboplatin 7irinotecan sucrosofate 6durvalumab 6dehydroftorafur 6Radiosurgery 6Pemetrexed 6olaparib 5Ipilimumab 5Erlotinib Hydrochloride 5trastuzumab deruxtecan 4aldesleukin 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Panitumumab × 90 days × Clear all
NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network

Phase 3 Recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡